Half Year Financial Statements

Open PDF
Stock Pro Medicus Ltd (PME.ASX)
Release Time 13 Feb 2025, 9:29 a.m.
Price Sensitive Yes
 Pro Medicus Reports Strong H1 FY2025 Results
Key Points
  • 42.7% increase in after-tax profit to $51.74m
  • 31.1% increase in revenue to $97.20m
  • Continued growth in North America, up 34.6%
Full Summary

Pro Medicus Limited reported a first half after tax profit of $51.74m, an increase of $15.49m (up 42.7%) compared to the same period last year. Revenue from contracts with customers for the 6-month period increased from $74.11m to $97.20m, an increase of 31.1%. Underlying profit before tax was $69.92m compared with $48.93m for the previous corresponding period, an increase of 42.9%. The company continued to grow its North American presence, with revenue up 34.6% and three major implementations completed. The company also won key contracts in North America with Lurie Children's Hospital, Trinity Health, and Duly Health and Care, as well as extending contracts with existing customers. The company's European revenue increased 0.8% compared to the same period last year, while the Australian business increased revenue by 10.8%. The company maintained its investment in research and development, highlighting its commitment to innovation and product development. Exam volumes, particularly in the US, continued to grow throughout the period, both through increases from existing customers and new customers. The company's cash reserves increased by $24.48m despite an increase of $5.23m in dividend payout during the period.

Guidance

The company reported an underlying profit before tax of $69.92m for the half year ended 31 December 2024.